Forge Biologics Unveils FUEL™ Platform, Revolutionizing AAV Gene Therapy Production with 6x Productivity Boost
October 3, 2024Forge Biologics has introduced its FUEL™ manufacturing platform, aimed at significantly enhancing the efficiency of AAV gene therapy production.
This innovative platform can boost productivity by 2 to 6 times compared to current industry standards for AAV gene therapies.
The FUEL™ platform integrates advanced technologies, including the pEMBR 2.0™ Ad helper plasmid and modified rep/cap plasmids, to optimize production processes.
Notably, the pEMBR 2.0™ Ad helper is one of the smallest commercially available at 8.9kb, which contributes to improved safety and manufacturing efficiency.
A critical component of the FUEL™ platform is Forge’s HEK293 suspension Ignition™ cell line, which enhances the speed and safety of AAV production.
John Maslowski, President & CEO of Forge, highlighted the platform's role in supporting clients throughout the development process, from discovery to clinical trials.
David Dismuke, Ph.D., Chief Technical Officer of Forge, praised the collaborative efforts of the team that led to the productivity gains achieved with the FUEL™ platform.
Data regarding the FUEL™ platform will be showcased at the upcoming Cell & Gene Meeting on the Mesa.
Maslowski is set to present the FUEL™ platform at the Alliance for Regenerative Medicine’s event on October 8, 2024, in Phoenix, Arizona.
Forge Biologics is based in Columbus, Ohio, and operates a 200,000 square foot facility specifically designed for scalable gene therapy manufacturing.
The platform's new modified rep/cap plasmids allow for the integration of client-specific capsid sequences into the proprietary backbone plasmid.
Summary based on 2 sources
Get a daily email with more Gene Therapy stories
Sources
Forge Biologics FUEL™ AAV Manufacturing Platform • Oct 2, 2024
Forge Biologics Announces the FUEL™ AAV Manufacturing Platform to Provide Developers with a More Efficient Solution for Gene Therapy Production